Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention
Seung Hun Lee, Young‐Hoon Jeong, David Hong, et al.
КАРДИОЛОГИЯ УЗБЕКИСТАНА (2023) Vol. 16, Iss. 7, pp. 829-843
Closed Access | Times Cited: 18

Showing 18 citing articles:

International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention
Dominick J. Angiolillo, Mattía Galli, Dimitrios Alexopoulos, et al.
КАРДИОЛОГИЯ УЗБЕКИСТАНА (2024) Vol. 17, Iss. 22, pp. 2639-2663
Closed Access | Times Cited: 9
Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel
Anil Pareek, Nitin Chandurkar, Vivek Raut, et al.
Open Heart (2025) Vol. 12, Iss. 1, pp. e003088-e003088
Open Access
Clopidogrel Versus Aspirin Monotherapy in High-Risk Patients after Percutaneous Coronary Intervention (SMART-CHOICE 3): A Randomised, Open-Label, Multicentre Trial
Ki Hong Choi, Yong Hwan Park, Jong‐Young Lee, et al.
(2025)
Closed Access
Comparative effectiveness of potassium-competitive acid blockers and proton pump inhibitors in dual antiplatelet therapy patients: a nationwide cohort study
Yu Jeong Lee, Nam Kyung Je
International Journal of Clinical Pharmacy (2025)
Closed Access
Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services
Trishna Patel, Eman Wehbe, Stephen Hughes, et al.
The Pharmacogenomics Journal (2025) Vol. 25, Iss. 3
Open Access
Renal Function-Stratified Comparison of Short- and Long-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention With Third-Generation Drug-Eluting Stents ― Post Hoc Analysis From the HOST-IDEA Randomized Clinical Trial ―
Jung‐Kyu Han, Seung Do Lee, Doyeon Hwang, et al.
Circulation Journal (2024)
Open Access | Times Cited: 2
Prognostic Impact of CYP2C19 Genotypes on Long‐Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention
Ju Hyeon Kim, Seung‐Jun Lee, Jung‐Joon Cha, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 10
Open Access | Times Cited: 1
A type of self-assembled and label-free DNA-modified electrochemical biosensors based on magnetic α-Fe2O3/Fe3O4 heterogeneous nanorods for ultra-sensitive detection of CYP2C19*3
Sihan Zhao, Peng Deng, Mingyi Ma, et al.
Bioelectrochemistry (2024) Vol. 160, pp. 108792-108792
Closed Access | Times Cited: 1
Impact of proton pump inhibitor use on clinical outcomes in East Asian patients receiving clopidogrel following drug-eluting stent implantation
Ju Hyeon Kim, Soon Jun Hong, Jung‐Joon Cha, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes
Hyun Kuk Kim, Seungeun Ryoo, Seung Hun Lee, et al.
Korean Circulation Journal (2024) Vol. 54
Closed Access | Times Cited: 1
Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention
Kevin K Cheng, Christian San Andres, Emen Salam, et al.
The American Journal of Cardiology (2023) Vol. 202, pp. 218-222
Closed Access | Times Cited: 1
Pharmacogenetics at scale in real-world bioresources: CYP2C19 and clopidogrel outcomes in UK Biobank
Khaled Bedair, Blair H. Smith, Nicholette D. Palmer, et al.
Pharmacogenetics and Genomics (2023) Vol. 34, Iss. 3, pp. 73-82
Closed Access | Times Cited: 1
Aiming for precision: CYP2C19 gene polymorphism and clopidogrel resistance in patients with peripheral artery disease
Sina Rashedi, Parham Sadeghipour, Junyang Lou
Thrombosis Research (2024) Vol. 236, pp. 240-241
Closed Access
A Phase 1 Study of Novel Antiplatelet Agent to Overcome Pharmacogenomic Limitations of Clopidogrel
Anil Pareek, Nitin Chandurkar, Vivek Raut, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention
Joshua J Park, Gervacio Y Cabel, Kevin K Cheng, et al.
Pharmacogenomics (2024) Vol. 25, Iss. 7, pp. 293-298
Closed Access
左心耳閉鎖デバイス留置1年半後にデバイス関連血栓症による脳塞栓症を呈した1例
Masahiro Tanaka, Shinji Sato, K Satake, et al.
Nosotchu (2024)
Open Access
Cytochrome СYP2C19 gene polymorphisms and bleeding in patients treated with clopidogrel as part of dual antithrombotic therapy after acute coronary syndrome
А. И. Кочетков, Valeria De, S. V. Batyukina, et al.
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice (2024), Iss. 3, pp. 55-67
Open Access
Genotype-Guided Selection of Antiplatelet Therapy
Larisa H. Cavallari, Francesco Franchi
КАРДИОЛОГИЯ УЗБЕКИСТАНА (2023) Vol. 16, Iss. 7, pp. 844-846
Open Access
Page 1

Scroll to top